Is SRRK or GMAB more profitable?

Genmab A/S has a net margin of 19.08% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Genmab A/S 19.08% 14.89% 7.73%

Does the media prefer SRRK or GMAB?

In the previous week, Genmab A/S had 3 more articles in the media than Scholar Rock. MarketBeat recorded 6 mentions for Genmab A/S and 3 mentions for Scholar Rock. Genmab A/S's average media sentiment score of 0.36 beat Scholar Rock's score of 0.17 indicating that Genmab A/S is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Genmab A/S 2 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Does the media prefer SRRK or UTHR?

In the previous week, United Therapeutics had 38 more articles in the media than Scholar Rock. MarketBeat recorded 41 mentions for United Therapeutics and 3 mentions for Scholar Rock. United Therapeutics' average media sentiment score of 0.42 beat Scholar Rock's score of 0.17 indicating that United Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral United Therapeutics 13 Very Positive mention(s) 11 Positive mention(s) 8 Neutral mention(s) 3 Negative mention(s) 1 Very Negative mention(s) Neutral

Does the media refer more to SRRK or ASND?

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.17 beat Ascendis Pharma A/S's score of -0.02 indicating that Scholar Rock is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Ascendis Pharma A/S 1 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 3 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has higher earnings & valuation, EXEL or SRRK?

Exelixis has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Exelixis $2.32B 6.26 $782.57M $3.18 18.43 Scholar Rock N/A N/A -$377.94M -$3.45 N/A

Is EXEL or SRRK more profitable?

Exelixis has a net margin of 35.33% compared to Scholar Rock's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Scholar Rock's return on equity. Company Net Margins Return on Equity Return on Assets Exelixis 35.33% 42.17% 31.76% Scholar Rock N/A -160.19% -87.18%

Does the media favor EXEL or SRRK?

In the previous week, Exelixis had 1 more articles in the media than Scholar Rock. MarketBeat recorded 4 mentions for Exelixis and 3 mentions for Scholar Rock. Exelixis' average media sentiment score of 0.74 beat Scholar Rock's score of 0.17 indicating that Exelixis is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Exelixis 1 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Scholar Rock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has better valuation and earnings, SRRK or SMMT?

Summit Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Scholar Rock N/A N/A -$377.94M -$3.45 N/A Summit Therapeutics N/A N/A -$1.08B -$1.12 N/A

Is SRRK or SMMT more profitable?

Scholar Rock's return on equity of -160.19% beat Summit Therapeutics' return on equity. Company Net Margins Return on Equity Return on Assets Scholar Rock N/A -160.19% -87.18% Summit Therapeutics N/A -168.94% -141.92%

Does the media favor SRRK or SMMT?

In the previous week, Summit Therapeutics had 17 more articles in the media than Scholar Rock. MarketBeat recorded 20 mentions for Summit Therapeutics and 3 mentions for Scholar Rock. Summit Therapeutics' average media sentiment score of 0.42 beat Scholar Rock's score of 0.17 indicating that Summit Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Scholar Rock 0 Very Positive mention(s) 1 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Summit Therapeutics 7 Very Positive mention(s) 3 Positive mention(s) 8 Neutral mention(s) 1 Negative mention(s) 1 Very Negative mention(s) Neutral

Scholar Rock (SRRK) Competitors

$46.81 +0.65 (+1.41%)

Closing price 04:00 PM Eastern

Extended Trading

$47.05 +0.24 (+0.51%)

As of 07:06 PM Eastern

Compare

SRRK vs. GMAB, UTHR, ASND, EXEL, and SMMT

Should you buy Scholar Rock stock or one of its competitors? Scholar Rock's main competitors and comparable companies include Genmab A/S (GMAB), United Therapeutics (UTHR), Ascendis Pharma A/S (ASND), Exelixis (EXEL), and Summit Therapeutics (SMMT). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Scholar Rock compare to Genmab A/S?

Scholar Rock (NASDAQ:SRRK) and Genmab A/S (NASDAQ:GMAB) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their valuation, profitability, earnings, dividends, institutional ownership, media sentiment, analyst recommendations and risk.

Scholar Rock has a beta of 0.61, meaning that its share price is 39% less volatile than the broader market. Comparatively, Genmab A/S has a beta of 0.81, meaning that its share price is 19% less volatile than the broader market.

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 7.1% of Genmab A/S shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 1.5% of Genmab A/S shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Genmab A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Genmab A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Genmab A/S	$3.72B	5.72	$963M	$1.27	26.86

Genmab A/S has a net margin of 19.08% compared to Scholar Rock's net margin of 0.00%. Genmab A/S's return on equity of 14.89% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Genmab A/S	19.08%	14.89%	7.73%

Scholar Rock presently has a consensus price target of $66.75, suggesting a potential upside of 41.51%. Genmab A/S has a consensus price target of $39.50, suggesting a potential upside of 15.78%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts plainly believe Scholar Rock is more favorable than Genmab A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Genmab A/S	0 Sell rating(s)	3 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.85

In the previous week, Genmab A/S had 3 more articles in the media than Scholar Rock. MarketBeat recorded 6 mentions for Genmab A/S and 3 mentions for Scholar Rock. Genmab A/S's average media sentiment score of 0.36 beat Scholar Rock's score of 0.17 indicating that Genmab A/S is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Genmab A/S	2 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Genmab A/S beats Scholar Rock on 10 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to United Therapeutics?

Scholar Rock (NASDAQ:SRRK) and United Therapeutics (NASDAQ:UTHR) are both healthcare companies, but which is the better investment? We will compare the two businesses based on the strength of their media sentiment, valuation, profitability, risk, institutional ownership, analyst recommendations, earnings and dividends.

Scholar Rock has a beta of 0.61, indicating that its stock price is 39% less volatile than the broader market. Comparatively, United Therapeutics has a beta of 0.49, indicating that its stock price is 51% less volatile than the broader market.

Scholar Rock currently has a consensus price target of $66.75, suggesting a potential upside of 41.51%. United Therapeutics has a consensus price target of $621.00, suggesting a potential upside of 12.60%. Given Scholar Rock's stronger consensus rating and higher probable upside, analysts clearly believe Scholar Rock is more favorable than United Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
United Therapeutics	1 Sell rating(s)	2 Hold rating(s)	11 Buy rating(s)	0 Strong Buy rating(s)	2.71

United Therapeutics has a net margin of 41.56% compared to Scholar Rock's net margin of 0.00%. United Therapeutics' return on equity of 20.18% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
United Therapeutics	41.56%	20.18%	17.98%

In the previous week, United Therapeutics had 38 more articles in the media than Scholar Rock. MarketBeat recorded 41 mentions for United Therapeutics and 3 mentions for Scholar Rock. United Therapeutics' average media sentiment score of 0.42 beat Scholar Rock's score of 0.17 indicating that United Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
United Therapeutics	13 Very Positive mention(s)	11 Positive mention(s)	8 Neutral mention(s)	3 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are owned by institutional investors. Comparatively, 94.1% of United Therapeutics shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by insiders. Comparatively, 8.6% of United Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

United Therapeutics has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than United Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
United Therapeutics	$3.18B	7.43	$1.33B	$27.95	19.73

Summary

United Therapeutics beats Scholar Rock on 10 of the 15 factors compared between the two stocks.

How does Scholar Rock compare to Ascendis Pharma A/S?

Scholar Rock (NASDAQ:SRRK) and Ascendis Pharma A/S (NASDAQ:ASND) are both healthcare companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, risk, analyst recommendations, profitability, earnings, media sentiment, institutional ownership and valuation.

Scholar Rock has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Ascendis Pharma A/S has a beta of 0.38, indicating that its share price is 62% less volatile than the broader market.

Ascendis Pharma A/S has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Ascendis Pharma A/S, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Ascendis Pharma A/S	$814.57M	17.38	-$258M	$12.89	17.60

91.1% of Scholar Rock shares are owned by institutional investors. 10.3% of Scholar Rock shares are owned by company insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.

In the previous week, Ascendis Pharma A/S had 6 more articles in the media than Scholar Rock. MarketBeat recorded 9 mentions for Ascendis Pharma A/S and 3 mentions for Scholar Rock. Scholar Rock's average media sentiment score of 0.17 beat Ascendis Pharma A/S's score of -0.02 indicating that Scholar Rock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ascendis Pharma A/S	1 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Ascendis Pharma A/S has a net margin of 70.99% compared to Scholar Rock's net margin of 0.00%. Ascendis Pharma A/S's return on equity of 32.54% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Ascendis Pharma A/S	70.99%	32.54%	7.71%

Scholar Rock currently has a consensus price target of $66.75, indicating a potential upside of 41.51%. Ascendis Pharma A/S has a consensus price target of $310.75, indicating a potential upside of 36.96%. Given Scholar Rock's higher possible upside, equities analysts clearly believe Scholar Rock is more favorable than Ascendis Pharma A/S.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Ascendis Pharma A/S	0 Sell rating(s)	1 Hold rating(s)	19 Buy rating(s)	1 Strong Buy rating(s)	3.00

Summary

Ascendis Pharma A/S beats Scholar Rock on 11 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Exelixis?

Exelixis (NASDAQ:EXEL) and Scholar Rock (NASDAQ:SRRK) are both healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, media sentiment, risk, earnings, dividends, valuation, profitability and analyst recommendations.

Exelixis has a beta of 0.47, meaning that its stock price is 53% less volatile than the broader market. Comparatively, Scholar Rock has a beta of 0.61, meaning that its stock price is 39% less volatile than the broader market.

In the previous week, Exelixis had 1 more articles in the media than Scholar Rock. MarketBeat recorded 4 mentions for Exelixis and 3 mentions for Scholar Rock. Exelixis' average media sentiment score of 0.74 beat Scholar Rock's score of 0.17 indicating that Exelixis is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Exelixis	1 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Exelixis has a net margin of 35.33% compared to Scholar Rock's net margin of 0.00%. Exelixis' return on equity of 42.17% beat Scholar Rock's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Exelixis	35.33%	42.17%	31.76%
Scholar Rock	N/A	-160.19%	-87.18%

85.3% of Exelixis shares are held by institutional investors. Comparatively, 91.1% of Scholar Rock shares are held by institutional investors. 2.6% of Exelixis shares are held by company insiders. Comparatively, 10.3% of Scholar Rock shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Exelixis presently has a consensus target price of $50.29, indicating a potential downside of 14.21%. Scholar Rock has a consensus target price of $66.75, indicating a potential upside of 41.51%. Given Scholar Rock's stronger consensus rating and higher possible upside, analysts clearly believe Scholar Rock is more favorable than Exelixis.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Exelixis	1 Sell rating(s)	12 Hold rating(s)	6 Buy rating(s)	1 Strong Buy rating(s)	2.35
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94

Exelixis has higher revenue and earnings than Scholar Rock. Scholar Rock is trading at a lower price-to-earnings ratio than Exelixis, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Exelixis	$2.32B	6.26	$782.57M	$3.18	18.43
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A

Summary

Exelixis beats Scholar Rock on 9 of the 16 factors compared between the two stocks.

How does Scholar Rock compare to Summit Therapeutics?

Scholar Rock (NASDAQ:SRRK) and Summit Therapeutics (NASDAQ:SMMT) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their institutional ownership, dividends, valuation, risk, analyst recommendations, media sentiment, earnings and profitability.

Summit Therapeutics is trading at a lower price-to-earnings ratio than Scholar Rock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Scholar Rock	N/A	N/A	-$377.94M	-$3.45	N/A
Summit Therapeutics	N/A	N/A	-$1.08B	-$1.12	N/A

In the previous week, Summit Therapeutics had 17 more articles in the media than Scholar Rock. MarketBeat recorded 20 mentions for Summit Therapeutics and 3 mentions for Scholar Rock. Summit Therapeutics' average media sentiment score of 0.42 beat Scholar Rock's score of 0.17 indicating that Summit Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Scholar Rock	0 Very Positive mention(s)	1 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Summit Therapeutics	7 Very Positive mention(s)	3 Positive mention(s)	8 Neutral mention(s)	1 Negative mention(s)	1 Very Negative mention(s)	Neutral

91.1% of Scholar Rock shares are held by institutional investors. Comparatively, 4.6% of Summit Therapeutics shares are held by institutional investors. 10.3% of Scholar Rock shares are held by insiders. Comparatively, 83.5% of Summit Therapeutics shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Scholar Rock has a beta of 0.61, indicating that its share price is 39% less volatile than the broader market. Comparatively, Summit Therapeutics has a beta of -1.51, indicating that its share price is 251% less volatile than the broader market.

Scholar Rock's return on equity of -160.19% beat Summit Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Scholar Rock	N/A	-160.19%	-87.18%
Summit Therapeutics	N/A	-168.94%	-141.92%

Scholar Rock presently has a consensus target price of $66.75, indicating a potential upside of 41.51%. Summit Therapeutics has a consensus target price of $28.61, indicating a potential upside of 70.87%. Given Summit Therapeutics' higher probable upside, analysts plainly believe Summit Therapeutics is more favorable than Scholar Rock.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Scholar Rock	2 Sell rating(s)	1 Hold rating(s)	11 Buy rating(s)	4 Strong Buy rating(s)	2.94
Summit Therapeutics	1 Sell rating(s)	8 Hold rating(s)	9 Buy rating(s)	1 Strong Buy rating(s)	2.53

Summary

Scholar Rock beats Summit Therapeutics on 9 of the 14 factors compared between the two stocks.

Get Scholar Rock News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding SRRK and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

SRRK vs. The Competition

Export

Metric	Scholar Rock	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$5.70B	$3.84B	$7.09B	$13.24B
Dividend Yield	N/A	3.64%	2.53%	15.88%
P/E Ratio	-13.57	12.99	274.61	26.05
Price / Sales	N/A	1,288.54	600.52	89.39
Price / Cash	N/A	121.76	77.38	51.25
Price / Book	19.42	16.63	10.92	6.31
Net Income	-$377.94M	-$22.67M	$3.50B	$361.43M
7 Day Performance	-3.74%	-3.05%	-2.11%	-1.67%
1 Month Performance	-16.56%	-10.75%	-6.34%	-3.94%
1 Year Performance	33.02%	21.11%	8.81%	2.77%

Scholar Rock Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
SRRK Scholar Rock	2.6866 of 5 stars	$46.81 +1.4%	$66.75 +42.6%	+33.1%	$5.70B	N/A	N/A	289
GMAB Genmab A/S	4.2731 of 5 stars	$34.69 -0.1%	$39.50 +13.9%	+8.8%	$21.67B	$3.72B	27.32	3,029	Options Volume
UTHR United Therapeutics	3.9321 of 5 stars	$493.10 -0.3%	$646.00 +31.0%	+30.4%	$21.22B	$3.18B	17.64	1,400	Trending News Analyst Forecast Insider Trade
ASND Ascendis Pharma A/S	4.7691 of 5 stars	$237.59 +0.4%	$310.75 +30.8%	+11.4%	$14.77B	$814.57M	18.43	1,189
EXEL Exelixis	3.1761 of 5 stars	$57.22 -2.0%	$50.29 -12.1%	+40.6%	$14.46B	$2.32B	17.99	1,077

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:SRRK) was last updated on 10/2/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Scholar Rock (SRRK) Competitors

SRRK vs. GMAB, UTHR, ASND, EXEL, and SMMT

How does Scholar Rock compare to Genmab A/S?

Summary

How does Scholar Rock compare to United Therapeutics?

Summary

How does Scholar Rock compare to Ascendis Pharma A/S?

Summary

How does Scholar Rock compare to Exelixis?

Summary

How does Scholar Rock compare to Summit Therapeutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Scholar Rock (SRRK) Competitors

SRRK vs. GMAB, UTHR, ASND, EXEL, and SMMT

How does Scholar Rock compare to Genmab A/S?

Which has more volatility and risk, SRRK or GMAB?

Do insiders and institutionals hold more shares of SRRK or GMAB?

Which has preferable earnings and valuation, SRRK or GMAB?

Is SRRK or GMAB more profitable?

Do analysts prefer SRRK or GMAB?

Does the media prefer SRRK or GMAB?

Summary

How does Scholar Rock compare to United Therapeutics?

Which has more risk & volatility, SRRK or UTHR?

Do analysts rate SRRK or UTHR?

Is SRRK or UTHR more profitable?

Does the media prefer SRRK or UTHR?

Do institutionals and insiders hold more shares of SRRK or UTHR?

Which has stronger earnings and valuation, SRRK or UTHR?

Summary

How does Scholar Rock compare to Ascendis Pharma A/S?

Which has more volatility & risk, SRRK or ASND?

Which has preferable valuation & earnings, SRRK or ASND?

Do insiders and institutionals have more ownership in SRRK or ASND?

Does the media refer more to SRRK or ASND?

Is SRRK or ASND more profitable?

Do analysts rate SRRK or ASND?

Summary

How does Scholar Rock compare to Exelixis?

Which has more volatility and risk, EXEL or SRRK?

Does the media favor EXEL or SRRK?

Is EXEL or SRRK more profitable?

Do insiders & institutionals have more ownership in EXEL or SRRK?

Do analysts recommend EXEL or SRRK?

Which has higher earnings & valuation, EXEL or SRRK?

Summary

How does Scholar Rock compare to Summit Therapeutics?

Which has better valuation and earnings, SRRK or SMMT?

Does the media favor SRRK or SMMT?

Do institutionals & insiders believe in SRRK or SMMT?

Which has more risk and volatility, SRRK or SMMT?

Is SRRK or SMMT more profitable?

Do analysts rate SRRK or SMMT?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

SRRK vs. The Competition

Scholar Rock Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools